Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCIP24
|
|||
| Drug Name |
LDN-57444
|
|||
| Synonyms |
668467-91-2; CHEMBL3407553; LDN 57444; (Z)-3-(acetoxyimino)-5-chloro-1-(2,5-dichlorobenzyl)indolin-2-one; C17H11Cl3N2O3; LDN57444; Ubiquitin Thiolesterase L1 Inhibitor; Ubiquitin C-Terminal Esterase L1 Inhibitor; Ubiquitin C-Terminal Hydrolase L1 Inhibitor; SCHEMBL16249746; BDBM65518; AOB1095; EX-A700; 5-Chloro-1-[(2,5-dichlorophenyl)methyl]-1H-indole-2,3-dione 3-(O-acetyloxime); 2511AH; BDBM50514120; MFCD09037562; ZINC83434034; AKOS025295611; CS-3923; 3-(O-acetyloxime), 5-chloro-1-[(2,5-dichlorophenyl)methyl]-1H-Indole-2,3-dione; NCGC00247668-01; AC-32696; AS-56100; HY-18637; SW219408-1; LDN-57444, >=98% (HPLC); [(E)-[5-Chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Preclinical | [1] | |
| Company |
Brigham and Women's Hospital
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H11Cl3N2O3
|
|||
| Canonical SMILES |
CC(=O)ON=C1C2=C(C=CC(=C2)Cl)N(C1=O)CC3=C(C=CC(=C3)Cl)Cl
|
|||
| InChI |
1S/C17H11Cl3N2O3/c1-9(23)25-21-16-13-7-12(19)3-5-15(13)22(17(16)24)8-10-6-11(18)2-4-14(10)20/h2-7H,8H2,1H3/b21-16-
|
|||
| InChIKey |
OPQRFPHLZZPCCH-PGMHBOJBSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ubiquitin thioesterase L1 (UCHL1) | Target Info | Inhibitor | [2] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Parkinson disease | |||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| WikiPathways | Parkinsons Disease Pathway | |||
| Proteasome Degradation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78. | |||
| REF 2 | Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells. Int J Mol Sci. 2019 Jul 31;20(15):3733. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.